JAN 22, 2021 8:17 PM PST

Treating NF1: Investigational Drug Shows Positive Results

WRITTEN BY: Nouran Amin

From preclinical studies, researchers have found that an investigational drug called ‘cabozantinib’ can treat tumors form a genetic disorder known as neurofibromatosis type 1 (NF1).

"This is the second class of drugs to demonstrate a very promising response rate for NF1 patients with these tumors," said first author Fisher, Chief of the Section of Neuro-Oncology and Director of the Neurofibromatosis Program at CHOP, and Group Chair for the NF Clinical Trials Consortium, which includes 25 sites developing innovative biologically-based clinical trials for complications of NF. "Collectively, the data presented in this study illustrate a true bench-to-bedside approach, coordinating translational and clinical efforts to advance targeted therapies for a rare disease like NF1."

NF1 is a rare disease affecting approximately 1 in 3000 people globally and is characterized by a proliferation of tumors throughout the nervous system.

Learn more about NF1:

"It's incredibly exciting that we now have two classes of drugs that result in tumor responses, given that we had no promising agents only a few years ago," Dr. Fisher said. "However, despite this excitement, neither cabozantinib nor MEK inhibitors shrink all tumors or make them go away completely. Therefore, we are building on these results as well as ongoing laboratory studies and are planning future exploration of combination therapies, so that we can further improve outcomes for these patients with these debilitating and life-threatening tumors."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 09, 2021
Cannabis Sciences
Cannabis Alleviates Neuropathic Pain from Chemotherapy
MAR 09, 2021
Cannabis Alleviates Neuropathic Pain from Chemotherapy
Neuropathic pain from oxaliplatin-based chemotherapy regimens occurs in up to 90% of patients, and continued exposure to ...
MAR 18, 2021
Drug Discovery & Development
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
MAR 18, 2021
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
Researchers have developed a prototype for a new kind of cancer immunotherapy. The therapy uses engineered T-cells to ta ...
MAR 12, 2021
Drug Discovery & Development
Drug Starves Melanoma Tumors
MAR 12, 2021
Drug Starves Melanoma Tumors
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a drug candidate that blocks the uptake ...
MAR 24, 2021
Drug Discovery & Development
Three Compounds May Be Suitable for SARS-CoV-2
MAR 24, 2021
Three Compounds May Be Suitable for SARS-CoV-2
Researchers have found that that three common antiviral and antimalarial therapeutics may be effective in vitro at targe ...
MAR 30, 2021
Drug Discovery & Development
Common Alzheimer's Drugs Reduce Mortality Rate and Cognitive Decline
MAR 30, 2021
Common Alzheimer's Drugs Reduce Mortality Rate and Cognitive Decline
Researchers from the Karolinska Institute and Umea University in Sweden have found that a commonly recommended group of ...
APR 07, 2021
Drug Discovery & Development
Therapeutics Enhance The Body's Natural Killers
APR 07, 2021
Therapeutics Enhance The Body's Natural Killers
Most people who have been prescribed pain killers are familiar with fentanyl, oxycodone, and morphine. These substances ...
Loading Comments...